News

3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

3V

30 APRIL 2019 San Mateo, California, United States, and Hangzhou and Shaoxing, China, 30 April 2019 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced today that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code: ASC40) […]

Comments Off on 3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH Continue Reading →

GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel

logo-glyco

ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 29, 2019– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and […]

Comments Off on GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel Continue Reading →

GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

logo-glyco

Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapySecond initiation among three late-stage uproleselan clinical trials ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 23, 2019– GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement […]

Comments Off on GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML Continue Reading →

Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965

indalojpg

Oral integrin antagonist inhibits multiple processes of pathologic fibrosisIndalo to present at NASH Summit in Boston, MA, on April 24th Cambridge, MA, April 18, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today announced the […]

Comments Off on Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965 Continue Reading →

Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion

Catalent_Biologics-1080x675

Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning Catalent for accelerated long-term growth SOMERSET, N.J. and BALTIMORE, M.D. – April 15, 2019 – Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, […]

Comments Off on Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion Continue Reading →

MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies

MAXCYTE-New-Logo-2016-LARGE

MaxCyte, the global clinical-stage cell-based medicines and life sciences company, announced today the launch of the new ExPERT™ technology platform. This family of instruments – the ATx, STx and GTx – represents the next generation of the industry’s leading, clinically validated Flow Electroporation® technology for complex cellular engineering. With these additions to the product portfolio, […]

Comments Off on MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies Continue Reading →

Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing

Paragon

Appointments and Promotions Continue to Position Paragon as Industry-Leading Gene Therapy and Vaccine CDMO Paragon Bioservices, the leading private equity-backed, biologics contract development and manufacturing organization (CDMO) announced today the appointment of Thomas VanCott, Ph.D., as Chief Technology and Strategy Officer (CTSO), along with several key promotions and new hires. “We are thrilled to welcome Tom […]

Comments Off on Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing Continue Reading →

AURP Announces Brian Darmody as New CEO and Launches ‘AURP HQ2’ in Washington, DC Area

B Darmody

The Association of University Research Park, a professional association of university-related research and science parks, announced the appointment of Brian Darmody, Associate Vice President of Corporate Engagement at the University of Maryland (UMD), as its new Chief Executive Officer (CEO). Additionally, the association has opened a new office at the UMD Discovery District in the Washington, DC area, to […]

Comments Off on AURP Announces Brian Darmody as New CEO and Launches ‘AURP HQ2’ in Washington, DC Area Continue Reading →

Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO

Robert-Jacks_4268Cc-Web_for wire distro

Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today announced that Robert Jacks has been appointed President & CEO. Mr. Jacks brings to Indalo 18 years of experience in biopharmaceutical product development, corporate strategy, business development, […]

Comments Off on Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO Continue Reading →

PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast

King-Rachel-PVcom-FeaturedImage630x315-560x315

Rachel King has charted a unique career — from consultant to VC to startup to now CEO — and is leading a pioneering company in the use of glycobiology technology. Click here to listen to the podcast via Pharmavoice.com”

Comments Off on PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast Continue Reading →